{"id":57074,"date":"2026-02-13T13:16:53","date_gmt":"2026-02-13T05:16:53","guid":{"rendered":"https:\/\/flcube.com\/?p=57074"},"modified":"2026-02-13T13:16:54","modified_gmt":"2026-02-13T05:16:54","slug":"organon-reports-2025-revenue-decline-to-6-2-billion-jada-sale-and-portfolio-pressures-weigh","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57074","title":{"rendered":"Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh"},"content":{"rendered":"\n

Organon & Co.<\/strong> (NYSE:\u202fOGN<\/a><\/strong>) announced fourth quarter and full-year 2025 financial results<\/strong>, with total revenue declining 3% to USD\u202f6.2 billion<\/strong> on a constant currency basis<\/strong>. The women’s health-focused pharmaceutical company<\/strong> faced headwinds from NuvaRing erosion<\/strong>, established brand LOE impacts<\/strong>, and biosimilar pricing pressure<\/strong>, partially offset by fertility growth<\/strong> and Hadlima biosimilar gains<\/strong>. The JADA system sale to Laborie Medical Technologies<\/strong> (early\u202f2026) removes a USD\u202f74 million revenue contributor<\/strong>, though currency translation<\/strong> is expected to offset the loss<\/strong>.<\/p>\n\n\n\n

Financial Performance Summary<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change (CC)<\/th>Key Driver<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>USD\u202f6.2 billion<\/td>-3%<\/strong><\/td>Women’s Health decline; Established Brands LOE; Biosimilar pricing pressure<\/td><\/tr>
Q4 Revenue<\/strong><\/td>USD\u202f1.507 billion<\/td>-8%<\/strong><\/td>Quarterly deceleration; NuvaRing erosion acceleration<\/td><\/tr>
2026 Guidance<\/strong><\/td>USD\u202f6.2 billion; Adj. EBITDA USD\u202f1.9 billion<\/td>Flat<\/strong><\/td>JADA sale offset by currency; operational stabilization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Segment Performance<\/h2>\n\n\n\n

Women’s Health: -2% to USD\u202f1.752 Billion<\/h3>\n\n\n\n
Product<\/th>Performance<\/th>Strategic Context<\/th><\/tr><\/thead>
Fertility business<\/strong><\/td>Growth<\/td>Offsetting factor<\/strong>; market expansion<\/td><\/tr>
JADA system<\/strong><\/td>USD\u202f74 million<\/strong> (+contribution)<\/td>Sold to Laborie Medical Technologies (early\u202f2026)<\/strong>; postpartum hemorrhage device<\/td><\/tr>
NuvaRing<\/strong><\/td>-23% decline<\/strong><\/td>Generic competition<\/strong>; hormonal contraceptive market shift<\/strong> to IUDs\/implants<\/td><\/tr>
Nexplanon<\/strong><\/td>-4% decline<\/strong><\/td>Mature implant<\/strong>; pricing pressure<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Biosimilars: +5% to USD\u202f691 Million<\/h3>\n\n\n\n
Product<\/th>Performance<\/th>Lifecycle Stage<\/th><\/tr><\/thead>
Hadlima (adalimumab)<\/strong><\/td>Primary growth driver<\/strong><\/td>Humira biosimilar<\/strong>; recent launch momentum<\/strong><\/td><\/tr>
Renflexis (infliximab)<\/strong><\/td>-8% decline<\/strong><\/td>Mature<\/strong>; US\/EU pricing pressure<\/strong><\/td><\/tr>
Ontruzant (trastuzumab)<\/strong><\/td>-30% decline<\/strong><\/td>Mature<\/strong>; Herceptin biosimilar competition<\/strong>; oncology biosimilar commoditization<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Established Brands: -5% to USD\u202f3.691 Billion<\/h3>\n\n\n\n
Product<\/th>Contribution<\/th>Offsetting Factor<\/th><\/tr><\/thead>
Emgality (galcanezumab)<\/strong><\/td>Growth<\/td>CGRP inhibitor<\/strong>; migraine prevention<\/td><\/tr>
Vtama (tapinarof)<\/strong><\/td>Growth<\/td>Topical psoriasis<\/strong>; novel mechanism<\/td><\/tr>
Respiratory portfolio<\/strong><\/td>Decline<\/td>Generic erosion<\/strong>; inhaler pricing pressure<\/strong><\/td><\/tr>
Atozet (ezetimibe\/atorvastatin)<\/strong><\/td>LOE impact<\/strong><\/td>Europe and Japan exclusivity loss<\/strong>; statin commoditization<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Priorities & 2026 Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Financial Impact<\/th><\/tr><\/thead>
Portfolio Optimization<\/strong><\/td>JADA divestiture<\/strong> to Laborie; focus on core women’s health pharmaceuticals<\/strong><\/td>USD\u202f74 million revenue loss<\/strong>; offset by favorable FX<\/strong><\/td><\/tr>
Biosimilar Growth<\/strong><\/td>Hadlima expansion<\/strong>; international market penetration<\/strong>; new biosimilar launches<\/strong><\/td>Volume growth<\/strong> vs. pricing erosion trade-off<\/strong><\/td><\/tr>
Established Brands Defense<\/strong><\/td>Emgality\/Vtama growth acceleration<\/strong>; respiratory cost management<\/strong><\/td>Stabilization<\/strong> vs. continued LOE drag<\/strong><\/td><\/tr>
Operational Efficiency<\/strong><\/td>Adjusted EBITDA USD\u202f1.9 billion target<\/strong>; cost restructuring<\/strong><\/td>Margin preservation<\/strong> amid flat revenue<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Organon’s 2026 revenue stabilization, JADA divestiture execution, and biosimilar competitive positioning. Actual results may differ due to women’s health market dynamics, biosimilar pricing volatility, and currency translation variability.-Fineline Info & Tech<\/a><\/p>\n\n\n\n